Solana Co (NASDAQ: HSDT)

Helius Medical Technologies, Inc. (HSDT) is a company that operates in the neurotechnology industry, focused on neurological wellness. The company's primary product is the Portable Neuromodulation Stimulator (PoNS), a non-implantable medical device that delivers mild electrical stimulation to the surface of the tongue to provide treatment for gait deficit and chronic balance deficit.

Helius Medical Technologies operates in the neurotechnology industry, focusing on neurological wellness. The company's main business activities include the development and commercialization of the PoNS device, which is designed to treat gait deficit and chronic balance deficit in individuals with neurological disorders such as multiple sclerosis (MS), traumatic brain injury (TBI), and stroke. The company's operations span across the United States and Canada, where it has received marketing clearance and authorization for the PoNS device for various indications.

The PoNS device generates revenue for the company through its sale to individuals with neurological disorders, physical therapists, and rehabilitation centers. The device is used to treat a range of symptoms, including gait deficit, balance deficit, and cognitive impairment. Helius Medical Technologies has a strong competitive position in the market, with a unique product that has been shown to be effective in clinical trials. The company's competitive advantages include its proprietary waveform technology, strong intellectual property position, and a robust pipeline of products in development.

The company's primary customers are individuals with neurological disorders, including MS, TBI, and stroke, as well as physical therapists and rehabilitation centers. The PoNS device is used to treat a range of symptoms, including gait deficit, balance deficit, and cognitive impairment. Notable brand names and/or trade names of the company's products and services include the Portable Neuromodulation Stimulator (PoNS) and PoNS Therapy.